SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	01948/095002
	Serial No.	10/820,335
	Applicant	Robson et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	April 8, 2004
	Group	1614
	IDS Filed	January 13, 2006
(37 C.F.R. §1.98(b))	Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
WS	WO 00/23459	04/27/00	WIPO			
WS	WO 03/052121	06/26/2003	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

WS	Eltzschig et al., "Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium: Role of Ectonucleotidases and Adenosine A_{2B} Receptors," *J. Exp. Med.* 198:783-796 (2003).
	Enjyoji et al., "Targeted Disruption of cd39/ATP Diphosphohydrolase Results in Disordered Hemostasis and Thromboregulation," *Nat. Med.* 5:1010-1017 (1999).
	Gangadharan et al., "Targeting Platelet Aggregation: CD39 Gene Transfer Augments Nucleoside Triphosphate Diphosphohydrolase Activity in Injured Rabbit Arteries," *Surgery* 130:296-303 (2001).
	Goepfert et al., "CD39 Modulates Endothelial Cell Activation and Apoptosis," *Mol. Med.* 6:591-603 (2000).
	Goepfert et al., "Disordered Cellular Migration and Angiogenesis in cd39-Null Mice," *Circulation* 104:3109-3115 (2001).
	Hall et al., "A C-Terminal Motif Found in the β_2-Adrenergic Receptor, P2Y1 Receptor and Cystic Fibrosis Transmembrane Conductance Regulator Determines Binding to the Na^+/H^+ Exchanger Regulatory Factor Family of PDZ Proteins," *Proc. Natl. Acad. Sci. USA* 95:8496-8501 (1998).
	Imai et al., "Suppression of ATP Diphosphohydrolase/CD39 in Human Vascular Endothelial Cells," *Biochemistry* 38:13473-13479 (1999).
WS	Kegel et al., "An Ecto-ATPase and an Ecto-ATP Diphosphohydrolase are Expressed in Rat Brain," *Neuropharmacology* 36:1189-1200 (1997).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
	Attorney Docket No.	01948/095002
	Serial No.	10/820,335
	Applicant	Robson et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	April 8, 2004
	Group	1614
	IDS Filed	January 13, 2006
(37 C.F.R. §1.98(b))	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
WS	Koziak et al., "Palmitoylation Targets CD39/Endothelial ATP Diphosphohydrolase to Caveolae," *J. Biol. Chem.* 275:2057-2062 (2000).
WS	Laemmli, "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4," *Nature* 227:680-685 (1970).
WS	Mizumoto et al., "CD39 is the Dominant Langerhans Cell-Associated Ecto-NTPDase: Modulatory Roles in Inflammation and Immune Responsiveness," *Nat. Med.* 8:358-365 (2002).
WS	Robson et al., "Modulation of Extracellular Nucleotide-Mediated Signaling by CD39/Nucleotide Triphosphate Diphosphohydrolase-1," *Drug. Dev. Res.* 53:193-207 (2001).
WS	Sévigny et al., "Purification of the Blood Vessel ATP Diphosphohydrolase, Identification and Localisation by Immunological Techniques," *Biochim. Biophys. Acta.* 1334:73-88 (1997).

EXAMINER Walter Schlapkohl 2007.01.02 10:43:17 -05'00'	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.